Drug Profile
Research programme: C17-20 lyase inhibitors - ICR/BTG
Alternative Names: C17-20 lyase inhibitors - Institute of Cancer Research/British Technology GroupLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator The Institute of Cancer Research
- Developer BTG; The Institute of Cancer Research
- Class
- Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 28 May 1999 Preclinical development for Prostate cancer in United Kingdom (Unknown route)